NL2018741B1 - Light emitting device - Google Patents
Light emitting device Download PDFInfo
- Publication number
- NL2018741B1 NL2018741B1 NL2018741A NL2018741A NL2018741B1 NL 2018741 B1 NL2018741 B1 NL 2018741B1 NL 2018741 A NL2018741 A NL 2018741A NL 2018741 A NL2018741 A NL 2018741A NL 2018741 B1 NL2018741 B1 NL 2018741B1
- Authority
- NL
- Netherlands
- Prior art keywords
- light
- emitting device
- light emitting
- tissue
- emitting
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 6
- 230000003211 malignant effect Effects 0.000 claims abstract description 6
- 210000004969 inflammatory cell Anatomy 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000004744 fabric Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 53
- 206010028980 Neoplasm Diseases 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 9
- 230000004907 flux Effects 0.000 description 7
- 238000005286 illumination Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004980 dosimetry Methods 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012782 phase change material Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
- A61N2005/0627—Dose monitoring systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
Abstract
Light emitting device for illuminating a tissue of a subject, wherein the light emitting device is arranged to homogenously illuminate malignant cells, infectious agents or inflammatory cells of the tissue. For which purpose the light emitting device comprises a plurality of light emitting elements and wherein the plurality of light emitting elements comprises at least one light generating source.
Description
Octrooicentrum
Nederland
© 2018741 (21) Aanvraagnummer: 2018741 © Aanvraag ingediend: 19 april 2017 © BI OCTROOI © Int. CL:
A61N 5/06 (2017.01)
| 0 Aanvraag ingeschreven: | © Octrooihouder(s): |
| 29 oktober 2018 | JOBAST B.V. te Eelderwolde. |
| © Aanvraag gepubliceerd: | |
| - | © Uitvinder(s): |
| Selma Aletta van Dijk te Eelderwolde. | |
| © Octrooi verleend: | |
| 29 oktober 2018 | |
| © Gemachtigde: | |
| © Octrooischrift uitgegeven: | mr. ir. J. van Breda c.s. te Amsterdam. |
| 24 januari 2019 |
© Light emitting device
Light emitting device for illuminating a tissue of a subject, wherein the light emitting device is arranged to homogenously illuminate malignant cells, infectious agents or inflammatory cells of the tissue. For which purpose the light emitting device comprises a plurality of light emitting elements and wherein the plurality of light emitting elements comprises at least one light generating source.
NL Bl 2018741
Dit octrooi is verleend ongeacht het bijgevoegde resultaat van het onderzoek naar de stand van de techniek en schriftelijke opinie. Het octrooischrift komt overeen met de oorspronkelijk ingediende stukken.
Light emitting device
The invention relates to a light emitting device for illuminating a tissue of a subject and a method for treating a tissue of a subject.
Light emitting devices for illuminating tissue are known from common practice and applied during treatment of various tissues, in particular tumors.
A disadvantage of current pre- and post-operative treatment of solid tumors by either radio- or chemotherapy or a combination of both is that the efficacy of such a treatment is limited due to various resistance mechanisms. First, pressure inside a tumor is generally higher as compared to surrounding tissue. This limits the influx of any medicines or compounds in the tumor. Second, the tumor is hypoxic, which limits the efficacy of both chemo- and radiotherapy as no oxygen radicals produced by radiotherapy responsible for a cell killing effect can be formed inside the tumor. In addition, multidrug resistance pumps (MDRPs) become active in a hypoxic environment. Third, systemic side effects of chemo- or immunotherapy occur, as the active compound distributes through the whole body with a significant off-target effect. Consequently, current pre- and post-operative treatment of solid tumors by either radio- or chemotherapy or a combination of both is hampered by these effects, both in curative as well as palliative treatment of cancer. After neoadjuvant treatment by radiochemotherapy with unpredictable variable effects (i.e. complete response, partial response, no response), surgery is commonly performed for removing the tumor and its accompanying lymph nodes with the risk of leaving viable cancerous tissue behind due to a (non-) or partial responding tumor and the inability of a surgeon to reliably distinguish tumor tissue from healthy tissue.
It is therefore an object of the invention to provide a device and a method to reduce or diminish the aforementioned resistance mechanisms.
This object is achieved by a light emitting device for illuminating a tissue of a subject that is arranged to homogenously illuminate malignant cells of the tissue. Homoge nous illumination of malignant cells of a tissue, for example a cancer tumor, in combination with a targeted photodynamic agent results in an increased perfusion and oxygenation of the tumor. This enables to install radio- and/or chemotherapy at the optimal moment to allow more efficient cell killing at the tumor location. Homogenous illumination (i.e. uniform energy distribution per tumor area) allows for precise and individual administration of light at the tumor location and the light activatable compound in particular, while minimizing the amount of light and thus potentially a non-bound circulating light activatable compound administered to surrounding healthy tissue .
The light emitting device comprises a plurality of light emitting elements. As tissues vary in volumetric size and optical properties, multiple light emitting elements are advantageous to cover tissue having an uneven surface and to administer a precise field of light to that particular tissue.
The plurality of light emitting elements of the light emitting device comprises at least one light generating source. The at least one light generating source can be a xenon-based, laser-based or any other type of light source.
The light emitting device comprises at least one light generating source that is optically connected to the plurality of light emitting elements. Optically connecting the at least on light generating source to the plurality of light emitting elements is advantageous, as at least one light generating source is required and may also suffice for multiple light emitting elements. This reduces the complexity and required costs of the device.
The light emitting elements can be arranged in a twodimensional array. Such an orientation of light emitting elements is particularly suited for illuminating a flat surface of a tissue, for example the skin of a patient or a surface like the internal abdominal wall.
The light emitting elements can also be arranged in a three-dimensional array, wherein the light emitting elements are for example, arranged in a cylindrical orientation. This allows 360° illumination of internal tissues. The light emitting device can be endoscopically applied to treat internal tissues and organs such as oral tissues, respiratory tracts, esophagus, duodenum, pancreas, bile ducts, liver, small bowel, large bowel, sigmoid, rectum, anus, genitourinary system, and others. Moreover, such a light emitting device is compatible with magnetic resonance imaging (MRI).
The light emitting device comprises a controller that is arranged to control an emitted radiant flux of the device. A light dosimetry algorithm is used to control this emitted radiant flux. This algorithm is based on a preoperative clinical positron emission tomography (PET), and/or computed tomography (CT) X-ray, and/or ultrasound, and/or optoacoustic and/or magnetic resonance imaging (MRI) volumetric tissue map and its derived imaging properties per tissue type which are correlated with known optical properties of tissue described in terms of the absorption coefficient, μΆ (cm1), the scattering coefficient μ3 (cm1) , wherein the absorption coefficient and scattering coefficient can be influenced by the presence and amount of tumor tissue, fat, muscle tissue, blood, oxyhemoglobin, vasculature, bone, etc., the scattering function p(0, ψ) (sr1), where Θ is the deflection angle of scatter and ψ is the azimuthal angle of scatter and the real refractive index of the tissue, n'. The algorithm takes into account the individual optical properties of the tissue to be illuminated and the optical properties of the surrounding tissue to deliver a precision light bundle creating a controlled field of light delivery.
The plurality of light emitting elements of the light emitting device can be embodied as fiber-optic cables. This is a cost effective solution to distribute the light from the at least one light generating source to multiple light emitting elements .
The light emitting device is arranged to emit light having a wavelength between 350 to 900 nm, preferably between 660 and 740 nm, most preferable about 700 nm. In order to induce photo-immunotherapy, light having a wavelength from 350 to 900 nm is needed to activate a photodynamic therapy compound or photo-pharmacological agent. Generally, a suitable dose of irradiation is at least 1 J cmz at a wavelength of 660 - 740 nm. Near infrared light (light having a wavelength of approximately 700 nm) has the advantage that it penetrates deeper into tissue and has reduced light scattering and absorption properties. Such a wavelength allows penetration varying from millimeters to centimeters of otherwise inaccessible diseased tissues, such as tumors, infection sites, cardiovascular or inflammatory diseases located within the body of a subj ect.
The at least one light generating source of the light emitting device can comprise at least one light emitting diode. Light emitting diodes are cheap to manufacture and are flexible with regard to their emitted wavelength. This provides additional possibilities to precisely control the light output of the light emitting device for various tissue types.
Preferably, the at least one light emitting diode is a near-infrared (NIR) light emitting diode. Besides deeper tissue penetration and reduced light scattering and absorption, NIR is able to activate tumor-targeted agents, such as NIR 700DX, or other photodynamic therapy agents. These agents can be injected as an individual compound or conjugated to antibodies, nanobodies, polymers, nanoparticles (e.g. micells) or peptides which target a specific tissue. The agent is as such a targeted photo-immunotherapy or photo-activatable (nanoswitch) compound.
The light emitting device is arranged to emit light having a total radiant flux per unit surface area between 20 mW/cm2 and 500 mW/cm2. Near infrared (NIR) light with a density of 2.2 mW cm”2 (2.2 mJ s”1 cm”2) induces cell death. Assuming an attenuation coefficient of 4 cm”1, corrected for absorption (μ3) and scattering properties (μ3) , the intensity of the light applied would be down to 10% at a distance from the light emitting device to the to be treated tissue of 5.8 mm and down to 1% at 12 mm. Therefore, the dose of light emitted by the light emitting device is preferably at least 20 mW cm”z or higher, such as at least 50 mW cm”y 100 mW cm'/ 150 mW cm”2, 2 00 mW cm”2, 2 50 mW cm”2, or 300 mW cm”/
The light emitting device has a shape selected from the group consisting of a cylindrical shape, a bracelet-like shape, a strip shape, a dome-like shape. A cylindrical shape allows endoscopic application of the light emitting device, whereas a bracelet-like shape allows illumination of external areas of the body, such as upper and lower arms, joints, such as knees and elbows, upper and lower leg, neck, and other areas of the body. A strip-like shape can be placed at various positions on the body and its size and length can be varied. A dome-like shape, which can be based on a collapsible design with incorporated fiber optics at connection points of overlapping areas of illumination, can be applied to the breast of a patient to treat tissue of the breast. Due to the collapsible design, the device can be conveniently stored when not in use .
In another aspect the invention relates to a method for treating a tissue of a subject, comprising: bringing a light emitting device in proximity of the tissue of the subject and illuminating the tissue with the light emitting device with light having a wavelength between 350 nm and 900 nm. The subject is preferably a human who has cancer, a cardiovascular disease, an infection, or another disease or condition.
Preferably, a photo-activatable agent is administered to the subject prior to illumination of the tissue. The photoactivatable agent can be an agent suited for photodynamic therapy (PDT), photo-immunotherapy (PIT) and/or photopharmacology (i.e. activation or de-activation of chemical compounds or light-sensing nanoswitches), plasmonic nanostructures and phase change materials, light activatable nanomotors for drug delivery purposes by light or any other electromagnetic wave. The type of administration can be topical, by injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, intratumoral, intravenous), oral, sublingual, rectal, transdermal, intranasal, vaginal, via inhalation routes, or other types. As a specific tissue area is illuminated, any photo-activatable agent in that area is activated by the light emitting device and acts on the specific tissue area, while in surrounding tissue areas, the photo-activatable agent remains inactive.
In another embodiment of the invention, the administered the photo-activatable agent is a targeted agent such as a nanobody, or peptide. The targeted agent binds specifically to a desired tissue and is activated by the light emitting de vice in a controlled manner provided by the light dosimetry algorithm. Similarly, the light emitting device can also be used for photo-deactivation of medical compounds for purposes of photo-pharmacology. The combination of administering a targeted agent and the decreased pressure and increased oxygen content in the treated tissue, makes this method suitable to treat tissues affected by, but not limited to, breast cancer, head- and neck cancer, pancreatic cancer, esophageal cancer, gastric cancer, rectal cancer, vulvar cancer, cervical cancer, endometrial cancer, bladder and prostate cancer, and other conditions .
Preferably, the light emitting device is introduced endoscopically in the subject's body. Endoscopic introduction does not require surgery, while tissues can be accessed with relative ease.
The invention will hereinafter be further elucidated with reference to the drawing of exemplary embodiments of a light emitting device according to the invention that is not limiting as to the appended claims.
In the drawing:
- figure 1 shows a light emitting device according to the invention that can be externally applied to a subject;
- figure 2 shows another light emitting device according to the invention;
- figure 3 shows a light emitting device according to figure 1 wherein both ends are connected to each other;
- figure 4A shows a light emitting device according to the invention having a dome-like shape; and
- figure 4B shows a light emitting device according to figure 4A wherein that is collapsed.
whenever in the figures the same reference numerals are applied, these numerals refer to the same parts.
With reference to figure 1 the light emitting device 1 is arranged to homogenously illuminate malignant cells of a tissue. The light emitting device 1 is shaped as a strip having an attachment means 2, such that one end of the light emitting device 1 can be attached to another end of the light emitting device to form a bracelet-like shape suitable to wrap around an external body part such as an arm, leg, or neck.
The light emitting device 1 comprises a plurality of light emitting elements 3. This plurality of light elements 3 allows the homogenous illumination of a tissue of a patient wherein the size of the tissue exceeds the size of a single light emitting element 3.
With reference to figure 2, the plurality of light emitting elements 3 of the light emitting device comprises at least one light generating source 4. The plurality of light emitting elements 3 are embodied as panels having multiple LED/laser-based light points. These panels are connected to each other by tread clicking connections 5.
The at least one light generating source 4 is optically connected to the plurality of light emitting elements 3. This allows the usage of a single light generating source 4 to distribute light to all light emitting elements 3 hence increasing the efficiency of the light emitting device 1.
Referring to figure 1 and 2 the light emitting elements 3 are arranged in a two-dimensional array. In this arrangement, the light emitting device 1 is suited to illuminate a substantially flat surface of a tissue.
By connecting the light emitting device 1 to itself, the light emitting elements 3 can be arranged in a threedimensional array, as shown in figure 3. The light emitting device 1 is covered by a transparent cover sheet 7 and a cooling tube 6 is placed within the circumference of the light emitting device 1 to dissipate heat from the light emitting elements by circulation of circulation of a cooling medium such as water or any other coolant or cooling technology.
The light emitting device 1 comprises a controller that is arranged to control an emitted radiant flux of the device. This controller can be embodied as a computer that is electrically connected to the light emitting device 1 and that uses a light dosimetry algorithm to determine and set the emitted radiant flux of the light emitting device based on characteristics of the to be illuminated tissue.
The plurality of light emitting elements 3 can be embodied as fiber-optic cables. Fiber-optic cables form a costeffective solution to distribute light from one or a few sources efficiently over a larger surface.
The light emitting device 1 is arranged to emit light having a wavelength between 350 to 900 nm, preferably between 660 and 740 nm, most preferable about 700 nm. The advantage of light having a wavelength of approximately 700 nm is that it penetrates deeper into tissue and has reduced light scattering and absorption properties which is advantageous as less power is required to emit an effective amount of light. This reduces the required cooling capacity to maintain a temperature of the light emitting device that is suited for the body of a patient .
The at least one light generating source 4 comprises at least one light emitting diode. Light emitting diodes (LEDs) are efficient in their conversion of electric energy into light, and as such generate little heat in comparison to their light output, which in turn reduces the required cooling capacity.
The at least one light emitting diode is preferably a near-infrared (NIR) light emitting diode. NIR LEDs emit nearinfrared light having a wavelength of approximately 700 nm.
The light emitting device 1 is arranged to emit light having a total radiant flux per unit surface area between 20 mW/cirt and 500 mW/ciri. This range of radiant flux is sufficient to thoroughly illuminate most tissues of a patient.
The light emitting device 1 has a shape selected from the group consisting of a cylindrical shape, a bracelet-like shape, a strip shape, a dome-like shape. With reference to figure 4A, a light emitting device having a dome-like shape is shown. The light emitting device is suitable to illuminate a breast of a patient and can be collapsed as shown in figure 4B to ensure easy storage of the device 1.
Although the invention has been discussed in the foregoing with reference to an exemplary embodiment of the light emitting device of the invention, the invention is not restricted to this particular embodiment which can be varied in many ways without departing from the invention. The discussed exemplary embodiment shall therefore not be used to construe the appended claims strictly in accordance therewith. On the contrary the embodiment is merely intended to explain the wording of the appended claims without intent to limit the claims to this exemplary embodiment. The scope of protection of the invention shall therefore be construed in accordance with the appended claims only, wherein a possible ambiguity in the wording of the claims shall be resolved using this exem- plary embodiment.
Claims (17)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2018741A NL2018741B1 (en) | 2017-04-19 | 2017-04-19 | Light emitting device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2018741A NL2018741B1 (en) | 2017-04-19 | 2017-04-19 | Light emitting device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2018741B1 true NL2018741B1 (en) | 2018-10-29 |
Family
ID=59295261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2018741A NL2018741B1 (en) | 2017-04-19 | 2017-04-19 | Light emitting device |
Country Status (1)
| Country | Link |
|---|---|
| NL (1) | NL2018741B1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5944748A (en) * | 1996-07-25 | 1999-08-31 | Light Medicine, Inc. | Photodynamic therapy apparatus and methods |
| US7033381B1 (en) * | 1991-11-20 | 2006-04-25 | Erik Larsen | Photodynamic stimulation device and method |
| US20070260296A1 (en) * | 2004-09-13 | 2007-11-08 | William Porter | Apparatus for Photodynamic Therapy |
| US20080033412A1 (en) * | 2006-08-01 | 2008-02-07 | Harry Thomas Whelan | System and method for convergent light therapy having controllable dosimetry |
| US20110184336A1 (en) * | 2008-09-29 | 2011-07-28 | Tom Kerber | Device for photodynamical therapy of cancer |
| US20140350454A1 (en) * | 2011-12-19 | 2014-11-27 | Photocure Asa | Irradiation apparatus |
-
2017
- 2017-04-19 NL NL2018741A patent/NL2018741B1/en active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7033381B1 (en) * | 1991-11-20 | 2006-04-25 | Erik Larsen | Photodynamic stimulation device and method |
| US5944748A (en) * | 1996-07-25 | 1999-08-31 | Light Medicine, Inc. | Photodynamic therapy apparatus and methods |
| US20070260296A1 (en) * | 2004-09-13 | 2007-11-08 | William Porter | Apparatus for Photodynamic Therapy |
| US20080033412A1 (en) * | 2006-08-01 | 2008-02-07 | Harry Thomas Whelan | System and method for convergent light therapy having controllable dosimetry |
| US20110184336A1 (en) * | 2008-09-29 | 2011-07-28 | Tom Kerber | Device for photodynamical therapy of cancer |
| US20140350454A1 (en) * | 2011-12-19 | 2014-11-27 | Photocure Asa | Irradiation apparatus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bansal et al. | In vivo wireless photonic photodynamic therapy | |
| Dobson et al. | Photodynamic therapy and diagnosis: Principles and comparative aspects | |
| US20220176148A1 (en) | Device for delivering precision phototherapy | |
| Allison et al. | Oncologic photodynamic therapy: clinical strategies that modulate mechanisms of action | |
| ES2252423T3 (en) | PHOTODYNAMIC STIMULATION DEVICE. | |
| US8292935B2 (en) | Photonic device and method for treating cervical dysplasia | |
| CN100496640C (en) | Photodynamic therapy apparatus, method for controlling photodynamic therapy apparatus, and photodynamic therapy method | |
| US9649504B2 (en) | Implantable CLIPT illumination system | |
| US20230173301A1 (en) | Method and system for concurrent photothermal ablation and interstitial photodynamic therapy | |
| US20240123253A1 (en) | Photodynamic therapy devices, systems and methods | |
| KR20110054413A (en) | Apparatus and method for photo-diagnosis and phototherapy of skin disease | |
| NL2018741B1 (en) | Light emitting device | |
| US20190038909A1 (en) | A Therapeutic Method and Device Therefor | |
| US10195459B2 (en) | Device for photodynamical therapy of cancer | |
| CA2775660C (en) | Device for photodynamical therapy of cancer | |
| BR112016025468B1 (en) | APPARATUS FOR CONDUCTING A METHOD FOR TREATMENT | |
| CA2996501A1 (en) | System and method for administering light therapy to curved and large surfaces | |
| KR102344388B1 (en) | Light Delivering Device for Tissue Treatment | |
| JP2013208331A (en) | Photodynamic therapy system accompanying temperature adjustment | |
| Hashimoto et al. | Novel After‐loading Interstitial Photodynamic Therapy of Canine Transmissible Sarcoma with Photofrin II and Excimer Dye Laser | |
| Fujita et al. | Anatomically adjustable device for large-area photodynamic therapy | |
| Ho | Wireless Light Delivery for Photodynamic Therapy | |
| Allrdice et al. | Light delivery systems for adjunctive intraoperative photodynamic therapy | |
| Hu et al. | Biological effects of light-emitting diode light sources and their progress in clinical research | |
| Edge et al. | Biophotonic Therapy Induced Photobiomodulation |